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Panax ginseng is one of the most universally used herbal medicines in Asian and Western countries. Most
of the biological activities of ginseng are derived from its main constituents, ginsenosides. Interestingly, a
number of studies have reported that ginsenosides and their metabolites/derivativesdincluding ginse-
noside (G)-Rb1, compound K, G-Rb2, G-Rd, G-Re, G-Rg1, G-Rg3, G-Rg5, G-Rh1, G-Rh2, and G-Rp1dexert
anti-inﬂammatory activities in inﬂammatory responses by suppressing the production of proin-
ﬂammatory cytokines and regulating the activities of inﬂammatory signaling pathways, such as nuclear
factor-kB and activator protein-1. This review discusses recent studies regarding molecular mechanisms
by which ginsenosides play critical roles in inﬂammatory responses and diseases, and provides evidence
showing their potential to prevent and treat inﬂammatory diseases.
Copyright  2017, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The immune response is the most important defense system
protecting the human body from external attacks by microorgan-
isms and toxic chemical compounds. In order for this function to
work properly, it is necessary to distinguish pathogens from the
body’s own cells or tissues. However, pathogens can avoid the
immune system through various mechanisms. Therefore, multiple
approaches that recognize and neutralize pathogens have been
developed to overcome these difﬁculties. The immune system uses
a layered defense strategy against infection based on gradually
increasing speciﬁcity for invading organisms [1]. Innate immunity
is the ﬁrst line of defense, composed of four kinds of barriers:
physical, physiological, phagocytosis, and inﬂammation (Table 1).
Innate immunity acts mainly to detect invading microorganisms by
recognizing their pathogen-associated molecular patterns [2], and
therefore acts in a comprehensive manner against pathogens. In
addition, the immune response is not long-lasting [3]. Adaptive
immunity, also known as acquired immunity, is the second line of
defense and has two important processes that are distinguished
from those of innate immunity: presenting antigens andof Genetic Engineering, Sungkyun
echo@skku.edu (J.Y. Cho).
ork.
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016), http://dx.doi.org/10.101developing immunological memory (Table 2) [4]. Adaptive immu-
nity is divided into two types of immune responses: humoral im-
mune response and cell-mediated immune response [5]. The
humoral immune response is mediated by antibodies produced by
B cells in body ﬂuids, which collaboratewith complements secreted
by hepatocytes or macrophages [4,6]. The cell-mediated immune
response refers to the process in which immune cells detect and
destroy nonself cells [7], and consists of two responses. Of the two,
the antigen-speciﬁc reaction is caused by cytotoxic T cells that are
produced to destroy antigen-displaying cells by recognizing major
histocompatibility complex class I molecule- and endogenous
antigen-presenting cells, whereas nonspeciﬁc reactions take place
when major histocompatibility complex class II molecules and
exogenous antigens are presented on the cell membrane. In this
response, helper T cells are produced and secrete interleukins and
cytokines to stimulate B cells [8]. In turn, the stimulated B cells
produce antigen-speciﬁc antibodies and activate natural killer cells
and macrophages to eliminate the infected cells [9].
Ginseng, a perennial plant belonging to genus Panax, family
Araliaceae, has been used as a popular herbal medicine for thou-
sands of years. Ginseng is known to promote vitality, prolong life,kwan University, Suwon 16419, Korea. Mi-Yeon Kim, School of Systems Biomedical
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
main active components of Panax ginseng, in inﬂammatory responses
6/j.jgr.2016.08.004
Table 1
The four barriers of innate immunity
Physical barriers Skin Skin epidermis prevents pathogen invasion
Skin pH maintained between 3 and 5 by sebum to inhibit growth of pathogens
Mucosal membrane Mucosal membrane traps pathogens
Physiological barriers Temperature Temperature affects survival of invading pathogens
pH Acidic environment of stomach kills pathogens
Chemical mediators Lyse cell walls of invading pathogens
Phagocytosis Neutrophils, macrophages, dendritic cells
Inﬂammation Clearing invading pathogens via complex events
Table 2
Innate versus adaptive immunity
Innate immunity Adaptive immunity
Speciﬁcity Broad speciﬁcity Narrow speciﬁcity
Memory Absent Present (ampliﬁed in second response)
Cells Macrophages, dendritic cells, neutrophil cells B and T lymphocytes
Reaction time Immediate response Delayed response
Receptors Encoded in the germline
(LPS receptor, N-formyl methionyl receptor, mannose receptor,
and scavenger receptor)
Encoded by somatic genes diversiﬁed by somatic recombination (TCR, Ig)
Ig, immunoglobulin; LPS, lipopolysaccharide; TCR, T cell receptor.
J Ginseng Res 2016;-:1e92and show effects against a variety of conditions, including
depression, diabetes, fatigue, aging, inﬂammation, internal degen-
eration, nausea, tumors, pulmonary problems, dyspepsia, vomiting,
nervousness, stress, and ulcers [10e14]. There are up to 13 plants
afﬁliated with the genus Panax, with just ﬁve of them used thera-
peutically: Panax ginseng, American ginseng, Vietnamese ginseng,
Japanese ginseng, and Pseudoginseng. Among these ﬁve, P. ginseng
is most commonly used for the purpose of treatment, being used in
16.6% of 3,944 prescriptions reported in the Korean Clinical Phar-
macopoeia, written in 1610 A.D. [15]. The pharmacological effects of
ginseng are derived from multiple active ingredients, including
ginsenosides, ginsengosides, polysaccharides, peptides, phytos-
terols, polyacetylenes, polyacetylenic alcohols, and fatty acids
[16,17].
The ginsenosides are the major active pharmacological com-
ponents of ginseng [18]. Ginsenosides, also known as steroid-like
saponins, are unique to ginseng species. There are more than 100
ginsenosides, which are expressed by Rx. The X is determined by
the distance of movement on a thin-layer chromatography plate
in vitro: the most polar segment is marked A, whereas the least
polar is H [19]. Ginsenosides are classiﬁed into four groups based
on their backbone types (Fig. 1). Diverse sugar molecules are
attached to different areas of the four backbones to produce
distinctive ginsenoside molecules (Table 3). Various studies have
been conducted to understand the pharmacological mechanisms
of ginseng and ginsenosides in cardiovascular disease, diabetes
mellitus, cancers, stress, and immunostimulation [18]. The anti-
inﬂammatory role of ginseng, however, remains poorly under-
stood. Therefore, the pharmacological functions of ginseng and
ginsenosides in inﬂammatory responses are discussed in this
review.
2. Inﬂammatory responses and cytokines
Inﬂammation is a protective response of the body to remove
harmful stimuli, including damaged cells, pathogens, and irritants
[20], and is one of the physical barriers of innate immunity. Infec-
tion by pathogens is a main cause of inﬂammatory responses, but
injury or trauma (in the absence of parasitic infection) and expo-
sure to foreign particles, irritants, and pollutants are also potentPlease cite this article in press as: Kim JH, et al., Role of ginsenosides, the
and diseases, Journal of Ginseng Research (2016), http://dx.doi.org/10.10inducers of inﬂammation [21]. Inﬂammation is a well-orchestrated
biological reaction that consists of multiple steps. The ﬁrst step is
the recognition of external stimuli. This is mainly achieved by
germ-line encoded receptors, such as Toll-like receptors (TLRs) and
leucine-rich-repeat-containing receptors (NLRs) [22e24]. These
receptors detect pathogen- or damage-associated molecular pat-
terns, then activate receptors to stimulate a series of signaling
cascades, including nuclear factor-kappa B (NF-kB) and activator
protein-1 (AP-1) pathways. These transcriptional factors induce the
expression of proinﬂammatory cytokines, such as tumor necrosis
factor-alpha (TNF-a), interleukin-1b (IL-1b), interleukin-6 (IL-6),
and interferon-gamma (IFN-g). Consequently, cytokines facilitate
the recruitment of effector immune cells to the site of inﬂamed
tissue, and in turn, these effector cells create a cytotoxic environ-
ment to remove the invading pathogens by releasing toxic chem-
icals, including highly reactive oxygen species (ROS) and nitrogen
species.
Inﬂammation is essential to restore tissue homeostasis, and
therefore may cause serious diseases when it is not tightly regu-
lated. For example, genetic deﬁciencies in primary regulators of
inﬂammation increase susceptibility to infection in humans, such
as neutropenia. A study using knockout mice revealed that defects
in proinﬂammatory cytokines and effector-encoding genes increase
the risk of severe infection [25]. In contrast, immoderate inﬂam-
mation results in devastating impacts by causing unnecessary
collateral damage. An example corresponding to this effect is
chronic inﬂammation, in which acute inﬂammation persists for
more than 4 weeks. Chronic inﬂammation is caused by persistent
injury or infection, prolonged exposure to a toxic agent, or auto-
immune disease, which can induce various diseases, such as cancer
and diabetes (Fig. 2) [26e29].
3. Anti-inﬂammatory effects of ginsenosides
3.1. Ginsenoside-Rb1
Ginsenoside-Rb1 (G-Rb1), a main component of P. ginseng, in-
hibits TNF-a production in lipopolysaccharide (LPS)-stimulated
RAW264.7 macrophages, indicating that G-Rb1 is a potential anti-
inﬂammatory agent [30,31]. G-Rb1 also suppresses the activationmain active components of Panax ginseng, in inﬂammatory responses
16/j.jgr.2016.08.004
Fig. 1. Classiﬁcation of ginsenosides based on backbone types.
Table 3
Classiﬁcation of ginsenosides
Class Backbone type Representative ginsenosides
Protopanaxadiol type Dammarane backbone Ginsenoside-Ra1-3, G-Rb1-2, and G-Rh2-3
Protopanaxatriol type Additional hydroxyl group on C6 in a dammarane backbone Ginsenoside-Re, G-Rf, and G-Rg1
Oleanolic acid type Pentacyclic triterpenoid base Ginsenoside-Ro
Ocotillol type Five-membered epoxy ring at C20 Makonoside-Rs from Vietnamese ginseng
J.H. Kim et al / Ginsenosides and inﬂammatory responses 3of NF-kB, which is a key regulator of inﬂammation, as well as a
controller of TNF-a production in LPS-activated murine peritoneal
macrophages [32]. The activation of IL-1 receptor-associated kinase
(IRAK)-1, an inhibitor of kB (IkB) kinase (IKK)-a, NF-kB, and
mitogen-activated protein kinases (MAPKs), is also signiﬁcantly
decreased by G-Rb1. However, G-Rb1 does not affect the interaction
between LPS and TLR4 and the activation of IRAK-4 and IRAK-2 [32].
In addition, G-Rg1 exhibits in vivo anti-inﬂammatory effects in a
2,4,6-trinitrobenzene sulfuric acid (TNBS)-induced colitis animal
model by inhibiting IRAK activation-mediated inﬂammatory re-
sponses [32].
Osteoporosis is a bone loss disease characterized by decreased
bone strength and increased bone fragility [33]. Osteoporosis oc-
curs as a result of a variety of endocrine, metabolic, and mechanical
factors [34]. However, the inﬂuence of inﬂammation on bone
turnover has also emerged. In particular, inﬂammatory diseases
such as immunological dysfunctions, autoimmune and chronic in-
ﬂammatory diseases, HIV infection, hyper-immunoglobulin E (IgE)
syndrome, rheumatoid arthritis, hematological diseases (particu-
larly myeloma), and inﬂammatory bowel diseases are related to
osteoporosis [35e39]. Inﬂammation mainly regulates bone
remodeling through two mechanisms [40]. (1) Proinﬂammatory
cytokines play roles as ﬁnal regulators of osteoclast function. For
example, the receptor activator of NF-kB ligand (RANKL), also
known as TNF-related activation-induced cytokine, belongs in
this category. (2) Regulation of macrophage colony stimulating
factor controls osteoclastogenesis [41]. Interestingly, G-Rb1 exertsPlease cite this article in press as: Kim JH, et al., Role of ginsenosides, the
and diseases, Journal of Ginseng Research (2016), http://dx.doi.org/10.101antiosteoporotic activity by inhibiting the RANKL-stimulated
osteoclast differentiation from RAW264.7 macrophages. G-Rb1
suppresses RANKL-induced c-Jun N-terminal kinases (JNKs), p38
MAPK, and NF-kB pathways, and consequently blocks the expres-
sion of c-Fos and NF of activated T cells (NFAT) C1, which are
essential factors for the differentiation of osteoclasts [42].
3.2. Compound K
Compound K (CK), a bacterial metabolite of G-Rb1, exhibits anti-
inﬂammatory effects mainly by reducing inducible nitric oxide
synthase (iNOS), cyclooxygenase (COX)-2, and proinﬂammatory
cytokines [32,43,44]. CK suppresses the expression of proin-
ﬂammatory cytokines by downregulating the activities of IRAK-1,
MAPKs, IKK-a, and NF-kB in LPS-treated murine peritoneal mac-
rophages [32]. CK also suppresses the expression of iNOS and COX-
2 by inhibiting NF-kB signaling in LPS-stimulated RAW264.7 cells
[45]. In zymosan-treated bone-marrow-derived macrophages
(BMDMs) and RAW264.7 cells, CK inhibits inﬂammatory responses
by negatively regulating the secretion of proinﬂammatory cyto-
kines, the activation of MAPKs, and the generation of ROS [43]. In
addition, anti-inﬂammatory activity of CK has been observed in
LPS-stimulatedmicroglial cells. CK hinders inﬂammatory responses
by controlling both the generation of ROS and the activities of
MAPKs, NF-kB, and AP-1 [44].
The anti-inﬂammatory activities of CK have been explored in
a variety of inﬂammation-associated animal models. CKmain active components of Panax ginseng, in inﬂammatory responses
6/j.jgr.2016.08.004
Fig. 2. Diseases associated with chronic inﬂammation.
J Ginseng Res 2016;-:1e94downregulates 12-O-tetradecanoylphorbol-13-acetate-induced
ear edema by regulating the activities of NF-kB and COX-2 [46].
CK negatively regulates intestinal inﬂammation by modulating
NF-kB signaling in both a TNBS-induced colitis animal model and
a dextran sulfate sodium-induced colitis animal model [32,47].
Moreover, CK protects mice from endotoxin-induced lethal shock
by inhibiting the production of proinﬂammatory cytokines
[43,48].3.3. Ginsenoside-Rb2
Ginsenoside-Rb2 (G-Rb2) signiﬁcantly inhibits the production
of TNF-a in LPS-stimulated RAW264.7 cells and differentiated U937
cells with IC50 values of 27.5 mM and 26.8 mM, respectively [31]. In
addition, G-Rb2 has been reported to exert neuroprotective effects
in LPS-stimulated N9 microglial cells by blocking TNF-a production
[49]. G-Rb2 inhibits activation of IkBa, indicating that G-Rb2-
mediated downregulation of TNF-a production in microglia is
achieved by NF-kB inhibition, which may be a basic mechanism for
the anti-inﬂammatory activity of G-Rb2 [49].3.4. Ginsenoside-Rd
Ginsenoside-Rd (G-Rd) has also shown neuroprotective effects.
Similar to G-Rb2, G-Rd also suppresses LPS-stimulated NF-kB acti-
vation and TNF-a expression in N9 cells [49]. In addition, G-Rd ex-
erts neuroprotective effects in a ratmodel of transient focal cerebral
ischemia by regulating an early free radical scavenging pathwayand
a late anti-inﬂammatory response. G-Rd also decreases the forma-
tion of hydroxyl radicals, the early accumulation of DNA and pro-
tein, and lipid peroxidation. G-Rd suppresses inﬂammatory
responses in later stages after ischemia by the inhibiting the
expression of iNOS and COX-2 [50]. Moreover, G-Rd deceases in-
ﬂammatory responses in LPS-treated RAW264.7 cells. G-Rd reduces
NO generation, PGE2 production, and NF-kB activity [51].Please cite this article in press as: Kim JH, et al., Role of ginsenosides, the
and diseases, Journal of Ginseng Research (2016), http://dx.doi.org/10.103.5. Ginsenoside-Re
Ginsenoside-Re (G-Re) shows anti-inﬂammatory effects by
inhibiting interactions between LPS and TLR4 on macrophages. G-
Re suppresses LPS-mediated phosphorylation and degradation of
IRAK-1, and sequentially blocks IKK-a phosphorylation, NF-kB
activation, and the expression of proinﬂammatory cytokines, such
as TNF-a and IL-1b [52].
LPS-induced inﬂammatory response is closely associated with
neurodegenerative diseases, including Parkinson disease, Alz-
heimer disease (AD), and multiple sclerosis. It has been known that
LPS activates microglial cells in the central nervous system [53,54].
G-Re exerts a protective effect against neuroinﬂammation in the
central nervous system by inhibiting proinﬂammatory mediators
(iNOS and COX2) generated by LPS and blocking the p38 MAPK
signaling pathway in BV2 microglial cells, indicating that G-Re
could be a promising medication to treat neuroinﬂammatory dis-
eases [55]. G-Re is curative in a TNBS-induced colitis mouse model.
Oral administration (20 mg/kg) of G-Re is effective against LPS-
induced systemic inﬂammation in a TNBS-induced colitis mouse
model. G-Re dramatically inhibits the expression of IL-1b and TNF-
a, as well as NF-kB activation, and suppresses colon shortening and
myeloperoxidase activity in a colitis mouse model [52].
3.6. Ginsenoside-Rg1
Ginsenoside-Rg1 (G-Rg1) modulates microglial activation,
which plays a critical role in neurodegenerative diseases. G-Rd1
negatively regulates the production of TNF-a and NO as well as the
expression of iNOS and ionized calcium-binding adapter molecule
1 (Iba-1) by inhibiting the activation of NF-kB andMAPKs pathways
in mice when LPS is intracerebroventricularly injected [56]. In
accordance, G-Rg1 also suppresses the expression of iNOS, COX-2,
TNF-a, IL-1b, and NF-kB in LPS-stimulated BV-2 microglial cells.
Interestingly, PLC-g1 inhibitor partially eliminates the suppressive
effect of G-Rg1 in the LPS-mediated activation of IkB-a, cAMP
response element-binding protein (CREB), extracellular signal-
regulated kinase 1/2 (ERK1/2), JNK, and p38 MAPK, indicating
that PLC signaling may be associated with the inhibitory activity of
G-Rb1 for microglial activation [57,58]. The inhibitory activity of G-
Rg1 on inﬂammation has also been examined in macrophages. G-
Rg1 suppresses the expression of both IL-6 mRNA and protein by
inhibiting the NF-kB signal pathway in both LPS-stimulated
RAW264.7 cells and mouse peritoneal macrophages. In contrast,
G-Rb1 increases TNF-a expression by activating themTOR signaling
pathway in LPS-stimulated macrophages [59]. These results
strongly suggest that G-Rg1 plays a pivotal role in macrophage-
mediated inﬂammatory responses with different modes of ac-
tions by modulating signaling pathways of NF-kB or Akt/mTOR.
In vivo anti-inﬂammatory function of G-Rg1 has also been
demonstrated in inﬂammatory animal models. G-Rg1 effectively
ameliorates the symptoms of alcoholic hepatitis and TNBS-induced
colitis in animal models by inhibiting the activation of the NF-kB
signaling pathway, as consistently observed in vitro [60,61].
Recently, it was reported that G-Rb1 protects diverse tissues
from ischemia/reperfusion (IR) injury by regulating inﬂammatory
response and apoptosis. G-Rb1 protects the liver against IR injury in
rats by modulating NF-kB and ROSeNOehypoxia-inducible factor
signaling pathways [62,63]. Cerebral IR injury is also ameliorated by
G-Rb1 activating peroxisome proliferator-activated receptor-g/
heme oxygenase-1 (HO-1) or suppressing protease-activated re-
ceptor-1 expression in rat hippocampus [64,65]. Moreover, G-Rg1
shows a protective effect against cerebral IR injury by modulating
the activation of p38 MAPK [66]. These results suggest that G-Rg1
has therapeutic potential for IR injury.main active components of Panax ginseng, in inﬂammatory responses
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Ginsenoside-Rg3 (G-Rg3) shows suppressive effects in neuro-
degenerative conditions by preventing inﬂammatory neurotoxicity
and microglial activation. G-Rg3 signiﬁcantly suppresses TNF-a
expression and NF-kB activation in Abeta42-activated BV-2
microglial cells. The survival rate of TNF-a-treated Neuro-2a cells
increased after pretreatment with G-Rg3 [67]. In addition, daily
administration of G-Rg3 for 21 days signiﬁcantly improves learning
and memory impairments induced by LPS injection into rat brains
by inhibiting the expression of inﬂammatory mediators in the
hippocampus [68].
Recent studies have reported the role of G-Rg3 in inﬂammasome
activation. Two optical isomers of G-Rg3, 20(R)-Rg3 and 20(S)-Rg3,
exhibit inhibitory effects on both S-nitrosylation of the nucleotide-
binding domain leucine-rich repeat-containing receptor pyrin
domain-containing 3 (NLRP3) inﬂammasome and lethal endotoxin-
induced shock by suppressing iNOS [69], whereas 20(R)-Rg3 and
20(S)-Rg3 suppress NO generation and iNOS expression. S-nitro-
sylation of the NLRP3 inﬂammasome proteins, such as NLRP3 and
caspase-1, is decreased by these G-Rg3 isomers in LPS-stimulated
peritoneal macrophages and BMDMs. Under long-term LPS expo-
sure, LPS-generates excessive NO that inhibits IL-1b production by
inducing inﬂammasome activation and Akt phosphorylation.
However, 20(R)-Rg3 and 20(S)-Rg3 prevent this event by blocking
the excessive generation of NO. Moreover, 20(R)-Rg3 and 20(S)-Rg3
reduce susceptibility to lethal endotoxin shock by modulating the
generation of NO in LPS-injected mice, strongly indicating that
these two optical isomers of G-Rg3 might be useful in therapeutic
approaches to treat oxidative stress-related diseases [69].
3.8. Ginsenoside-Rg5
Anti-inﬂammatory effects of ginsenoside-Rg5 (G-Rg5), a main
component of steamed ginseng, have been studied in the context
of lung inﬂammation. G-Rg5 reduces the expression of IL-1b, TNF-
a, COX-2, and iNOS, and phosphorylation of IRAK-1, IKK-a, and NF-
kB. The degradation of IRAK-1 and IRAK4 are decreased by G-Rg5
in LPS-stimulated alveolar macrophages [70]. According to an
experiment using Alexa Flour 594-conjugated LPS, G-Rg5 in-
terferes with the binding of LPS to macrophages. The expression of
TNF-a, IL-1b, iNOS, and COX-2, as well as the activation of NF-kB
are also suppressed by G-Rg5 (10 mg/kg) in the bronchoalveolar
lavage ﬂuid of LPS-injected mice [70]. Moreover, the anti-
inﬂammatory activity of G-Rg5 has been observed in TNF-a-
stimulated liver cells, and in HepG2 cells by inhibiting NF-kB, COX-
2, and iNOS (IC50 ¼ 0.61) [71].
Inhibitory effects of G-Rg5 in neuroinﬂammatory responses
have also been examined in a memory-impaired rat model induced
by streptozotocin (STZ). In particular, because cholinergic system
synthases such as choline acetyltransferase, hydrolytic enzymes
such as acetylcholinesterase, and imbalanced levels of insulin-like
growth factor 1 (IGF-1) and brain derived neurotrophic factor
(BDNF) are associated with impaired memory function, the regu-
latory effect of G-Rg5 on these molecules was investigated. G-Rg5
improves cognitive deﬁcits by downregulating AChE activity and
upregulating choline acetyltransferase activity in the cerebral cor-
tex and hippocampus of STZ-induced AD rats. Administration of 10
and 20 mg/kg of G-Rg5 signiﬁcantly increased the expression of
BDNF and IGF-1 in the brain tissue of AD rats. Moreover, amyloid
beta (Ab) deposition was decreased in the hippocampus and cere-
bral cortex of diseased rats. G-Rg5 suppresses STZ-induced
expression of COX-2 and iNOS, which are key inﬂammatory en-
zymes in neuroinﬂammation [72]. In addition, a protective effect of
G-Rg5 has been observed in scopolamine-induced memoryPlease cite this article in press as: Kim JH, et al., Role of ginsenosides, the
and diseases, Journal of Ginseng Research (2016), http://dx.doi.org/10.101impaired mice. In this model, G-Rg5 improves memory deﬁcits by
suppressing AChE activity and increasing BDNF expression and
CREB phosphorylation [73]. Taken together, these ﬁndings strongly
suggest that G-Rg5 is a potential drug candidate to treat AD.
Anti-inﬂammatory activity of G-Rg5 in skin tissue was also
investigated in in vitro atopic dermatitis models, such as TNF-a/IFN-
g-treated keratinocytes and LPS-stimulated macrophages. G-Rg5
dramatically inhibits the expression of thymus- and activation-
regulated chemokine (TARC/CCL17) in TNF-a/IFN-g-stimulated
HaCaT cells. LPS-induced generation of NO and ROS is also
decreased by G-Rg5 in RAW264.7 cells. In addition, G-Rg5 sup-
presses NF-kB/p38 MAPK/STAT1 signaling pathways, which are
critically involved in TARC/CCL17 expression and NO production
[74]. These results indicate that G-Rg5 exerts anti-inﬂammatory
activity in skin disease by blocking the NF-kB/p38 MAPK/STAT1
signal pathways.3.9. Ginsenoside-Rh1
The anti-inﬂammatory effects of ginsenoside-Rh1 (G-Rh1) act
mainly by suppressing the expression of COX-2 and iNOS [75,76]. In
particular, the molecular mechanism of G-Rh1-mediated iNOS in-
hibition is well demonstrated in microglial cells. In IFN-g-stimu-
lated BV2 microglial cells, G-Rh1 inhibits the activation of Janus
kinase (JAK)/STAT and ERK signaling and their downstream tran-
scriptional factors, including NF-kB, IRF-1, and STAT1, thereby
suppressing iNOS expression and neuroinﬂammation [76].
The inhibitory activity of G-Rh1 on oxazolone-induced atopic
dermatitis-like skin lesions in hairless mice has also been investi-
gated. G-Rh1 diminishes the serum levels of IgE and IL-6 in atopic
dermatitis-induced mice, and consequently, the inﬁltration of in-
ﬂammatory cells and granulation of mast cells signiﬁcantly
decrease. Furthermore, G-Rh1 (10 mg/kg, 20 mg/kg) improves the
symptoms of atopic dermatitis and ear swelling [77], suggesting
that G-Rh1 has potential as an anti-inﬂammatory agent for the
treatment of atopic dermatitis.3.10. Ginsenoside-Rh2
Ginsenoside-Rh2 (G-Rh2), an intestinal bacterial metabolite of
ginsenoside, has been reported to show anti-inﬂammatory activity
in microglial cells and astroglial cells. In murine BV-2 microglial
cells, G-Rh2 inhibits LPS/IFN-g-induced generation of NO as well as
the expression of iNOS, COX-2, TNF-a, and IL-1b, by regulating
protein kinase A (PKA)/AP-1 signal pathways [78]. Moreover, G-Rh2
also suppresses TNF-a-induced intercellular adhesion molecule 1
(ICAM-1) expression by suppressing the activities of both NF-kB
and JNK/AP-1 signaling pathways in human astroglial cells [79].
Interestingly, G-Rh2-mediated modulation of NF-kB signaling was
not observed in either murine microglial cells or human monocytic
cells, suggesting that G-Rh2 may inhibit the NF-kB signaling
pathway in a cell-speciﬁc manner [78,79].
The anti-inﬂammatory effects of G-Rh2 in allergic airway
inﬂammation have also been investigated in a murine asthma
model. G-Rh2 inhibits peribronchiolar inﬂammation, the recruit-
ment of airway inﬂammatory cells, cytokine production, total and
ovalbumin-speciﬁc IgE levels, and expression of aryl hydrocarbon
receptor, which are representative pathophysiological characteris-
tics of asthma. Activation of NF-kB and phosphorylation of p38
MAPK are also suppressed by G-Rh2 in this disease animal model
[80], indicating that G-Rh2 ameliorates allergic airway inﬂamma-
tion by inhibiting the activation of NF-kB and p38 MAPK. Taken
together, G-Rh2 may be useful for the treatment of inﬂammatory
airway diseases, such as asthma.main active components of Panax ginseng, in inﬂammatory responses
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Table 4
Summary of anti-inﬂammatory activities of ginsenosides
Ginsenosides Activities Models Mode of action Ref.
G-Rb1 Anti-inﬂammation LPS-treated RAW264.7 cells Inhibiting TNF-a production [30,31]
LPS-treated murine peritoneal macrophages Blocking activation of IRAL-1, IKK-b, NF-kB, and MAPKs [32]
TNBS-induced colitis mice Inhibiting IRAK-activated inﬂammatory response [32]
Anti-osteoporosis RANKL-treated osteoblasts differentiated from RAW264.7 cells Blocking expression of c-Fos and NFATc1 by regulating RANKL-induced JNK,
p38 MAPK, and NF-kB
[42]
Compound K Anti-inﬂammation LPS-treated murine peritoneal macrophages Blocking expression of proinﬂammatory cytokines by downregulating
activities of IRAK-1, MAPKs, IKK-b, and NF-kB
[32]
LPS-treated RAW264.7 cells Inhibiting expression of iNOS and COX-2 by suppressing NF-kB [45]
Zymosan-treated RAW264.7 cells and BMDMs Reducing proinﬂammatory cytokines, MAPKs, and ROS [43]
TPA-induced ear edema mice Inhibiting NF-kB and COX-2 [46]
TNBS-induced colitis mice Inhibiting NF-kB [32]
DSS-induced colitis mice Inhibiting NF-kB [47]
Endotoxin-induced lethal shock mice Decreasing expression of proinﬂammatory cytokines [43,48]
Anti-inﬂammation and
neuroprotective effect
LPS-treated microglial cells Suppressing ROS generation, MAPKs, NF-kB, and AP-1 [44]
G-Rb2 Anti-inﬂammation LPS-treated RAW264.7 and U937 cells Inhibiting TNF-a production [31]
Neuroprotective effect LPS-treated N9 microglial cells Suppressing TNF-a production via NF-kB inhibition [49]
G-Rd Anti-inﬂammation LPS-treated RAW264.7 cells Reducing production of NO and PGE2, and NF-kB activity. [51]
Neuroprotective effect LPS-treated N9 cells Suppressing TNF-a and NF-kB [49]
Transient focal cerebral ischemia rats Inhibiting expression of iNOS and COX-2 [50]
G-Re Anti-inﬂammation LPS-treated peritoneal macrophages Blocking IKK-b phosphorylation, NF-kB activation, and production of
proinﬂammatory cytokines
[52]
TNBS-induced colitis mice Inhibiting NF-kB, IL-1b, and TNF-a [52]
Anti-neuroinﬂammation LPS-treated BV2-microglial cells Suppressing iNOS, COX-2, and p38 MAPK [55]
G-Rg1 Neuroprotective effect LPS-treated BV-2 microglial cells Suppressing iNOS, COX-2, TNF-a, IL-1b, and NF-kB via PLC-g1 [57]
LPS-injected rats Inhibiting production of TNF-a, IL-1b, and NO via glucocorticoid receptor
signaling
[58]
LPS-injected mice Inhibiting expression of TNF-a, iNOS, and Iba-1 by blocking NF-kB and
MAPKs
[56]
Anti-inﬂammation LPS-treated RAW264.7 cells (1) Suppressing IL-6 expression by inhibiting NF-kB
(2) Increasing TNF-a expression by activation of Akt/mTOR
[59]
Alcohol-induced hepatitis mice Inhibiting NF-kB [60]
TNBS-induced colitis mice Inhibiting NF-kB [61]
Anti-ischemia reperfusion (IR)
injury
Liver IR injury mice Inhibiting NF-kB and ROS/NO/HIF [62,63]
Cerebral IR injury rats Activating PPAR-g/HO-1 [64]
Cerebral IR injury rats Suppressing PAR-1 expression [65]
Cerebral IR injury rats Modulating p38 MAPK [66]
G-Rg3 Neuroprotective effect Abeta42-treated BV-2 microglial cells Inhibiting TNF-a expression and NF-kB activation [67]
LPS-injected rats Improving learning and memory impairment by inhibiting expression of
proinﬂammatory mediators
[68]
Anti-inﬂammation LPS-treated peritoneal macrophages and BMDMs Suppressing S-nitrosylation of NLRP3 inﬂammasome by reducing NO
generation and iNOS expression
[69]
LPS-injected mice Reducing susceptibility to lethal endotoxin shock by regulating NO
generation
[69]
G-Rg5 Anti-lung inﬂammation LPS-treated alveolar macrophages Decreasing expression of IL-1b, TNF-a, COX-2, and iNOS by inhibiting NF-kB
pathway
[70]
TNF-a-treated HepG2 cells Inhibiting NF-kB, COX-2, and iNOS [71]
LPS-injected mice Inhibiting TNF-a, IL-1b, iNOS, COX-2, and NF-kB [70]
Anti-neuro inﬂammation STZ-induced memory impaired rats (1) Improving cognitive deﬁcits by downregulating AChE activity and up-
regulating ChAT activity
(2) Increasing expression of BDNF and IGF-1
(3) Decreasing Ab deposition
(4) Suppressing COX-2 and iNOS
[72]
Scopolamine-induced memory impaired mice Improving memory deﬁcits by suppressing AChE activity and increasing
BDNF expression and CREB phosphorylation
[73]
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and diseases, Journal of Ginseng Research (2016), http://dx.doi.org/10.101Unlike other ginsenosides, G-Rh2 exhibits low levels of oral
bioavailability and water solubility, and therefore sulfated de-
rivatives of G-Rh2 such as G-Rh2-B1 and G-Rh2-B2 have been
synthesized. These derivatives of G-Rh2 reduce LPS-induced pro-
duction of TNF-a, IL-6, and IL-1b as well as the activities of p38
MAPK, JNK, and NF-kB, showing greater anti-inﬂammatory effects
than that of G-Rh2 [81,82], in turn suggesting that improving
bioavailability and water solubility of ginsenosides could also
improve their anti-inﬂammatory effects.3.11. Ginsenoside-Rp1
Ginsenoside-Rp1 (G-Rp1) has been reported to show anti-
inﬂammatory effects mainly through modulating the activity of
NF-kB. G-Rh1 decreases the LPS-induced expression of IL-1b, COX-
2, and iNOS by suppressing NF-kB activity in RAW264.7 cells
[83,84]. Interestingly, G-Rp1-mediated inhibition of NF-kB activa-
tion has been achieved by suppression of IKK-a phosphorylation,
but not MAPK phosphorylation [83,84]. These results indicate that
G-Rh1 inhibits inﬂammatory responses speciﬁcally by inhibiting
NF-kB activation.4. Conclusion
Studies of the pharmacological roles of ginsenosides have
focused mostly on their anticancer, antioxidative, and immu-
nostimulatory activities. A number of recent studies, however,
have presented evidence showing that ginsenosides could be
used to prevent and treat a variety of inﬂammatory diseases via
anti-inﬂammatory functions (Table 4). In particular, considering
the action mechanisms of ginsenosides, they are expected to
regulate inﬂammatory responses primarily through the inhibi-
tion of the NF-kB signaling pathway. In LPS-stimulated macro-
phages and microglial cells, ginsenosides suppress the
production of proinﬂammatory cytokinases such as TNF-a, IL-1b,
and IL-6, as well as inﬂammatory enzymes, such as iNOS and
COX-2. The expression of these molecules is predominantly
regulated by NF-kB signaling pathways, where IRAK, IKKa/b, and
IkBa are included in inﬂammatory responses. According to the
results of many in vitro studies, ginsenosides exert anti-
inﬂammatory activities in a variety of in vivo animal models of
inﬂammatory diseases, and show promising protective effects in
animal models of colitis, alcohol-induced hepatitis, IR injury, and
impaired memory diseases. Furthermore, the biological activities
of ginsenoside metabolites, such as CK, G-Rh1, and G-Rh2, have
been observed in diverse inﬂammation models. CK is effective for
ameliorating symptoms in animal models of ear edema, colitis,
and lethal shock. G-Rh1 and G-Rh1 also exerted anti-
inﬂammatory effects in animal models of atopic dermatitis and
asthma.
In conclusion, studies of ginsenosides strongly indicate that
ginsenosides and their metabolites/derivatives could serve as
potent pharmaceutical agents to prevent and treat inﬂammatory
diseases.Conﬂict of interests
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